Ratings by H.C. Wainwright (Andres Maldonado)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/24/2026 | Verastem | VSTM | Maintain | Buy (Buy) |
|
Details | ||
| 6/23/2026 | Relmada Therapeutics Inc | RLMD | Maintain | Buy (Buy) |
|
Details | ||
| 6/18/2026 | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
6.60 (6.77) |
2.58% | Details | |
| 6/16/2026 | Engene Holdings Inc. | ENGN | Maintain | Buy (N/A) |
|
Details | ||
| 6/12/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (Buy) |
|
Details | ||
| 6/3/2026 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (Buy) |
|
Details | ||
| 5/20/2026 | Protara Therapeutics | TARA | Maintain | Buy (Buy) |
|
Details | ||
| 5/8/2026 | Engene Holdings Inc. | ENGN | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2026 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2026 | Protara Therapeutics | TARA | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2026 | Verastem | VSTM | Maintain | Buy (Buy) |
|
Details | ||
| 4/8/2026 | NovaBridge Biosciences | NBP | Maintain | Buy (Buy) |
|
Details | ||
| 4/7/2026 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2026 | Candel Therapeutics Inc. | CADL | Maintain | Buy (Buy) |
|
Details | ||
| 3/16/2026 | NovaBridge Biosciences | NBP | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2026 | Candel Therapeutics Inc. | CADL | Maintain | Buy (Buy) |
|
Details | ||
| 3/2/2026 | CG Oncology | CGON | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2026 | Immunitybio Inc | IBRX | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2026 | NovaBridge Biosciences | NBP | Maintain | Buy (N/A) |
|
Details | ||
| 2/4/2026 | Verastem | VSTM | New Coverage | Buy (N/A) |
6.30 (4.21) |
-33.17% | Details | |
| 1/26/2026 | Immunitybio Inc | IBRX | Maintain | Buy (N/A) |
|
Details | ||
| 1/26/2026 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 12/23/2025 | Engene Holdings Inc. | ENGN | Maintain | Buy (Buy) |
|
Details | ||
| 12/19/2025 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2025 | Syndax Pharmaceuticals | SNDX | Maintain | Buy (Buy) |
|
Details | ||
| 12/3/2025 | Engene Holdings Inc. | ENGN | Maintain | Buy (Buy) |
|
Details | ||
| 10/16/2025 | Syndax Pharmaceuticals | SNDX | New Coverage | Buy (N/A) |
15.04 (19.61) |
30.39% | Details | |
| 10/7/2025 | Candel Therapeutics Inc. | CADL | Maintain | Buy (Buy) |
|
Details | ||
| 9/30/2025 | Candel Therapeutics Inc. | CADL | Maintain | Buy (Buy) |
|
Details | ||
| 9/24/2025 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2025 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 9/12/2025 | Engene Holdings Inc. | ENGN | Maintain | Buy (Buy) |
|
Details | ||
| 9/10/2025 | Immunitybio Inc | IBRX | Maintain | Buy (Buy) |
|
Details | ||
| 9/8/2025 | Engene Holdings Inc. | ENGN | Maintain | Buy (Buy) |
|
Details | ||
| 9/8/2025 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 6/30/2025 | Candel Therapeutics Inc. | CADL | New Coverage | Buy (N/A) |
4.90 (9.08) |
85.31% | Details | |
| 6/20/2025 | Scholar Rock | SRRK | Maintain | Buy (Buy) |
|
Details | ||
| 6/16/2025 | Engene Holdings Inc. | ENGN | Maintain | Buy (Buy) |
|
Details | ||
| 6/4/2025 | Immunitybio Inc | IBRX | Maintain | Buy (Buy) |
|
Details | ||
| 5/9/2025 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2025 | Immunitybio Inc | IBRX | Maintain | Buy (Buy) |
|
Details | ||
| 3/31/2025 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 3/26/2025 | Mural Oncology | MURA | Maintain | Buy (N/A) |
|
Details | ||
| 3/25/2025 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 3/14/2025 | Immunitybio Inc | IBRX | Maintain | Buy (Buy) |
|
Details | ||
| 3/12/2025 | Immunitybio Inc | IBRX | New Coverage | Buy (N/A) |
2.82 (7.32) |
159.57% | Details | |
| 3/11/2025 | Engene Holdings Inc. | ENGN | Maintain | Buy (Buy) |
|
Details | ||
| 3/6/2025 | Immunitybio Inc | IBRX | New Coverage | Buy (N/A) |
3.06 (7.32) |
139.22% | Details | |
| 12/23/2024 | Engene Holdings Inc. | ENGN | New Coverage | Buy (N/A) |
5.83 (1.71) |
-70.67% | Details | |
| 12/6/2024 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 11/26/2024 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2024 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (Buy) |
|
Details | ||
| 11/13/2024 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2024 | Mural Oncology | MURA | New Coverage | Buy (N/A) |
3.72 (2.04) |
-45.16% | Details | |
| 10/8/2024 | Scholar Rock | SRRK | Maintain | Buy (N/A) |
|
Details | ||
| 9/17/2024 | CG Oncology | CGON | Maintain | Buy (Buy) |
|
Details | ||
| 7/2/2024 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (Buy) |
|
Details | ||
| 6/26/2024 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (Buy) |
|
Details | ||
| 2/14/2024 | CG Oncology | CGON | New Coverage | Buy (N/A) |
44.18 (65.73) |
48.78% | Details | |
| 3/27/2023 | Werewolf Therapeutics Inc. | HOWL | Maintain | Buy (N/A) |
|
Details | ||
| 9/19/2022 | Scholar Rock | SRRK | New Coverage | Buy (N/A) |
8.91 (51.27) |
475.42% | Details | |
| 6/2/2022 | Werewolf Therapeutics Inc. | HOWL | New Coverage | Buy (N/A) |
3.43 (0.36) |
-89.5% | Details |
